Sponsor: Kartos Therapeutics
Sponsor Study ID: KRT-232-118
Study Title: Phase 2/3 Study of Navtemadlin (MDM2i) in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer
CTO #: 103797
NCT Number: NCT05797831
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Female Genital
Study Objectives: To determine the navtemadlin Phase 3 dose. To compare the progression-free survival (PFS) by independent review committee (IRC) between navtemadlin and placebo. To evaluate the treatment effect of navtemadlin on PFS by IRC and investigator assessment. To evaluate the treatment effect of navtemadlin on PFS by investigator assessment.